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Physiological health must balance immunological responsiveness against foreign
pathogens with tolerance toward self-components and commensals. Disruption of this
balance causes autoimmune diseases/chronic inflammation, in case of excessive immune
responses, and persistent infection/immunodeficiency if regulatory components are over-
active. This homeostasis occurs at two different levels: at a resting state to prevent
autoimmune disease, as autoreactive effectorT-cells (Teffs) are only partially deleted in the
thymus, and during inflammation to prevent excessive tissue injury, contract the immune
response, and enable tissue repair. Adaptive immune cells with regulatory function (“reg-
ulatory T-cells”) are essential to control Teffs. Two sets of regulatory T cell are required
to achieve the desired control: those emerging de novo from embryonic/neonatal thymus
(“thymic” or tTregs), whose function is to control autoreactiveTeffs to prevent autoimmune
diseases, and those induced in the periphery (“peripheral” or pTregs) to acquire regula-
tory phenotype in response to pathogens/inflammation.The differentiation mechanisms of
these cells determine their commitment to lineage and plasticity toward other phenotypes.
tTregs, expressing high levels of IL-2 receptor alpha chain (CD25), and the transcription fac-
tor Foxp3, are the most important, since mutations or deletions in these genes cause fatal
autoimmune diseases in both mice and men. In the periphery, instead, Foxp3+ pTregs can
be induced from naïve precursors in response to environmental signals. Here, we discuss
molecular signatures and induction processes, mechanisms and sites of action, lineage
stability, and differentiating characteristics of both Foxp3+ and Foxp3− populations of reg-
ulatoryT cells, derived from the thymus or induced peripherally. We relate these predicates
to programs of cell-based therapy for the treatment of autoimmune diseases and induction
of tolerance to transplants.
Keywords: regulatoryT cells, Foxp3,Tr1,Th3, iTr35, interleukin-17, epigenetics, microRNA
INTRODUCTION
Physiological health requires a balance between immunological
responsiveness against foreign pathogens and tolerance toward
self-components and commensals. The immune system must
guarantee this homeostatic balance, since its disruption leads
to autoimmune diseases (AID) and chronic inflammation in
the event of excessive immune reactivity, on the one hand,
and persistent infection(s) and immunodeficiency on the other
(Figure 1).
Regulation of immune responses occurs concurrently at two
different levels: in the “pathogen-free” environment (where
“danger” is inherently internal), to maintain tolerance to self-
components, and in the “pathogen-containing” environment
(where “danger” is external), to prevent excessive tissue injury,
contract the immune response and enable tissue repair.
Central selection of the T cell repertoire imparts intrinsic
autoreactivity to adaptive immunity as only T cells capable of
recognizing self-MHC are positively selected for survival. Thus,
despite negative selection of strongly autoreactive thymocytes, the
mature immune system can clearly be demonstrated to contain T
cells with autospecificity (Muraro et al., 1997), necessitating active
regulation of these cells in the periphery. That autoreactive cells
exist in the neonatal circulation imparts an obligate requirement
for the presence of regulation from birth, a function ascribed to
non-redundant “thymically derived” regulatory T cells (tTregs).
Although tTregs have been the focus of the “immunoregula-
tion” literature in recent years, the adult T cell pool also contains
a series of other T cells with regulatory function, many of which
are induced to develop suppressive phenotypes in the periphery in
response to antigenic challenges and the local micro-environment.
Such“induced”regulatory T cells include induced Foxp3+ (iTregs)
and Foxp3− (Th3, Tr1, iTr35, and CD8+CD28−) populations of
cells.
In this review, we describe the origins and functions of differ-
ent T cells with regulatory function, detailing their properties. An
important note that is worth highlighting at the outset is one of
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FIGURE 1 | Model of immunological homeostasis. Disturbance of the
balance between pro-inflammatory and anti-inflammatory mechanisms is
shown at either end of the cartoon. On the one hand, excessive immune
responsiveness and/or deficiency in tolerogenic mechanisms can lead to
autoimmune diseases, chronic inflammation, and pregnancy failure. On the
other hand, weak immune responsiveness and/or excessive
tolerance-inducing machineries can result in in immunodeficiency,
characterized by recurrent, and/or overwhelming infections.
semantics. In this review, we refer to CD4+CD25hiFoxP3+ regu-
latory T cells as “Tregs.” As there have been recent calls for greater
clarity in the nomenclature of FoxP3+ regulatory T cells (Abbas
et al., 2013) (Table 1), we refer to thymically derived Tregs as
tTregs and peripherally derived Tregs as pTregs. All in vitro induced
FoxP3+ Tregs we will call iTregs. All other inducible regulatory T
cell populations will be referred to by their current internationally
accepted names, such as Tr1 cells.
FOXP3+ REGULATORY T CELLS
The relative importance of centrally derived tolerance-inducing T
cells was established by experiments between the late 1960s and
early 1980s where it was observed that thymectomy of mice on the
third day of life resulted in organ-specific autoimmune diseases
[the exact target organ(s) depending on the mouse strain used].
However, this did not occur if neonatal mice were thymectomized
on days 1 or 7 (Nishizuka and Sakakura, 1969; Kojima et al., 1976,
1980; Taguchi and Nishizuka, 1981) and day 3 thymectomized
mice would not develop autoimmunity after infusion of thymo-
cytes (Sakaguchi et al., 1982). These experiments suggested that
autoreactive T cells exit the thymus in the first 3 days of life fol-
lowed a few days later by a population of suppressor cells that
control the autoreactive cohort. These experiments were followed
by the first descriptions of Tregs by Sakaguchi et al. (1995, 1996) as
a circulating subset of CD4+ T cells expressing high levels of CD25
(the IL-2 receptor α-chain), which could prevent the development
of multi-organ autoimmune diseases (thyroiditis, gastritis, insuli-
tis, sialoadenitis, adrenalitis, oophoritis, glomerulonephritis, and
polyarthritis) and/or rodent graft-versus-host disease (GVHD)-
like wasting disease in thymectomized mice, by adoptive trans-
fer (Suri-Payer et al., 1998). This was an advance on previous
Table 1 | Recommendations forTreg cell nomenclature.
“Thymus-derived Treg cell (tTreg cell)” should be used instead of “natural
Treg cell (nTreg cell)”
“Peripherally derived Treg cell (pTreg cell)” should be used instead of
“induced or adaptive Treg cell (iTreg cell or aTreg cell)”
“In vitro induced Treg cell (iTreg cell)” should be used to clearly distinguish
between those Treg cell populations generated in vivo versus those
generated in vitro
Treg cell terms should be used only when there is definitive evidence
justifying their use
The development and use of new Treg cell terminology should be limited,
especially for subpopulations
Reproduced from Abbas et al. (2013).
observations that had identified the “rescuing” population as
Thy1+(CD90+) Lyt1+(CD5+) Lyt2− (CD8a−) Lyt3−(CD8b−)
(Sakaguchi et al., 1982) CD45RBlo (Morrissey et al., 1993). As
CD25 correlates positively with CD5 and negatively with CD45RB,
the identification of CD25 expression as a surface marker for
Tregs was biologically plausible. The subsequent identification of
humans and mice deficient in CD4+CD25hi cells (as a result of
mutations in the FOXP3 and Foxp3 genes respectively – see below),
which develop severe autoimmune diseases (Sakaguchi et al., 1995,
1996; Chatila et al., 2000; Wildin et al., 2001) strongly suggests that
these cells have a critical and non-redundant regulatory role in the
maintenance of self-tolerance.
Although CD25 expression was the original defining feature of
Tregs, CD25 is also expressed by antigen-experienced and recently
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activated conventional T cells with non-regulatory properties
(effector T cells, “Teff”). As a result, CD25 is of greatest sensitivity
when used to identify Tregs from naïve T cell populations, such
as human umbilical cord blood, or antigen-naïve animals. Thus,
in antigen-experienced mammals, only the top 2–5% of CD25
expressing CD4+ cells (CD25hi) contains genuine Tregs (Baecher-
Allan et al., 2001). Since the descriptions of Tregs, therefore,a num-
ber of additional markers have been proposed as Treg-specifying,
including cytotoxic T-lymphocyte antigen-4 (CTLA-4) (Wing
et al., 2008; Sakaguchi et al., 2009), GITR (glucocorticoid-induced
TNF receptor family related protein; TNFRSF18) (Shimizu et al.,
2002), CD39 (Deaglio et al., 2007), HLA-DR (Baecher-Allan and
Hafler, 2006), CD45RA (Miyara et al., 2009), and low expression of
CD127 (the IL-7 receptor α-chain) (Liu et al., 2006). While these
markers will not be the focus of this review, it is important to note
that none can be used as unambiguous identifiers of human Tregs;
however, they often identify subsets of Tregs with different (quan-
tities or mechanisms of) suppressive functions, implying that there
is considerable heterogeneity in human populations of Tregs. Such
heterogeneity and the lack of specific markers for the Treg lineage
remain the cornerstone of debates regarding whether Tregs are in
fact a distinct T cell lineage and/or a possibility in the life cycle of
many different T cells.
FORKHEAD BOX P3, THE KEY TRANSCRIPTION FACTOR OF TREGS
The Scurfy mouse (sf), an X-linked mutant strain, described in
1949 [cit. loc (Russell et al., 1959)], exhibits a series of autoimmune
features including skin scaliness, diarrhea, and death (between 2
and 4 weeks after birth) in association with CD4+ T cell hyper-
proliferation, multi-organ CD4+ cell infiltration (Blair et al.,
1994) and over-production of several inflammatory cytokines
(Kanangat et al., 1996). This fatal autoimmune lymphoprolif-
erative syndrome was found to map to a gene locus on the X
chromosome called Foxp3, which was described as a new mem-
ber of the forkhead/winged-helix family of transcription factors
(TF) (Brunkow et al., 2001). The Foxp3 gene is highly conserved
between species and a mutation in the human gene, FOXP3,
was identified as the causative factor responsible for the human
equivalent of Scurfy, the Immunodysregulation, Polyendocrinopa-
thy, and Enteropathy, X-linked syndrome (IPEX), also known
as X-linked autoimmunity and allergic dysregulation syndrome
(XLAAD) (Chatila et al., 2000; Bennett et al., 2001; Hori et al.,
2003). Both mouse and human diseases have deficient circulat-
ing Tregs, which suggests that Foxp3 and FOXP3 are essential for
normal Treg development in the two species respectively. This
position is strengthened by the failure of Foxp3 knockout mice to
develop circulating Tregs; these animals develop a Scurfy-like syn-
drome from which they can be rescued by the adoptive transfer of
Tregs from a Foxp3 replete animal (Fontenot et al., 2003). Further-
more, ectopic or over-expression of Foxp3 in CD4+CD25−mouse
cells results in the development of a Treg phenotype (Fontenot
et al., 2003; Hori et al., 2003; Khattri et al., 2003). In mice, Foxp3
expression is a good phenotypic marker of Tregs (Fontenot et al.,
2005c; Wan and Flavell, 2005); in humans, however, FOXP3 does
not allow the unambiguous identification of Tregs (Ziegler, 2006)
as it is induced during TCR stimulation in conventional CD4+ T
cells (Walker et al., 2003; Gavin et al., 2006; Wang et al., 2007) (in
much the same manner as CD25) and there has been some debate
as to whether the induced CD4+CD25+FOXP3+ population is
suppressive or anergic (Walker et al., 2003; Gavin et al., 2006).
Although Foxp3 may function as a transcriptional inhibitor
through associations with NFAT, NF-κB, and RORγt (Schubert
et al., 2001; Bettelli et al., 2005; Zhou et al., 2008a), its biological
function is still incompletely understood and will be discussed in
an accompanying review in this series. However, it is worth men-
tioning that the concept of Foxp3 as a “lineage-specifying factor”
of Tregs is an over-simplification, as suggested by three lines of evi-
dence: (i) Foxp3 is not sufficient in itself to determine the full Treg
transcriptional profile (Hill et al., 2007); (ii) Foxp3 is expressed by
(human) Teffs following activation, without imparting the pheno-
type associated with Tregs; (iii) humans with IPEX syndrome have
heterogeneous T cell abnormalities, including dysfunction in Teffs
(Bacchetta et al., 2006).
THYMICALLY DERIVED TREGS
Thymic education of T cells is a two step process involving, first,
positive selection of thymocytes recognizing self-MHC and, sec-
ond, negative selection of T cells with T cell receptors (TCRs) of
high avidity for class I and class II MHC molecules presenting self-
antigens. Thus, duration and avidity of the TCR interaction with
self-peptide-MHC complexes on antigen-presenting cells (APC)
determine thymocyte fate. Thymocytes that bind with high avidity
undergo programed cell death in an attempt to limit autoreac-
tivity in the periphery, while thymocytes with low avidity for
self-MHC:peptide are selected as effector T cells (Teff).
A thymic origin for Tregs was suggested by the neona-
tal thymectomy-induced autoimmunity models described above
(reviewed in Shevach, 2000). In addition, neonatal infection
of BALB/c mice with superantigen-expressing murine mam-
mary virus (MMV) results in increased numbers of Vβ6+ Tregs
(Papiernik et al., 1998), which implies that thymocyte interac-
tion with antigen preferentially favors Treg differentiation. Indeed,
interactions between TCR and MHC class II peptides are essential
for normal tTreg development (Sakaguchi et al., 2008; Josefow-
icz and Rudensky, 2009), an assertion which is consistent with
the observation that Tregs express molecules associated with an
activated state in Teffs (CD5, CD25, CTLA-4, and Foxp3) and
the binding of TCR/CD28-coupled TFs (e.g., NFAT and AP1) to
the Foxp3 promoter (Mantel et al., 2006). Thus, mice engineered
for high antigen expression, e.g., influenza haemaglutinin (HA),
and TCR specificity for that HA (i.e., I-Ed-restricted TCR spe-
cific for HA) develop large numbers of Tregs (Jordan et al., 2001),
indicating that self-agonist ligands, contrary to inducing clonal
deletion, or anergy, cause central development of Tregs. These
observations are corroborated by a high degree of self-reactivity
(against MHC/peptide complexes expressed on APCs) in Tregs
compared to other CD4+ populations (Romagnoli et al., 2002).
This demonstrates a biased thymically imprinted TCR repertoire
based on recognition of self-MHC-peptide, suggesting that nega-
tive selection in the thymus is incomplete, with thymocytes hav-
ing TCR-MHC:self-peptide interactions of intermediate strength
escaping deletion and differentiating into cells with a regulatory
phenotype (Tregs) (reviewed in Singer et al., 2008; Josefowicz et al.,
2012). There is now significant evidence that tTreg development
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is self-antigen driven, with the tTreg population being largely
autoreactive (Hsieh et al., 2004, 2006; Picca and Caton, 2005).
The high similarity between the TCR repertoire of Tregs found
within the thymus and Tregs isolated from the circulation (Hsieh
et al., 2006; Wong et al., 2007) is, therefore, indicative of thymic
Treg émigrés making a significant contribution to the peripheral
Treg pool.
A number of additional cues are required for thymic induc-
tion of Tregs, notably those providing co-stimulation or IL-2R-γc
cytokine family signaling. The importance of γc cytokines to tTreg
development is highlighted by the absence of this population
from the thymus and periphery of IL-2R-γc knockout animals
(Fontenot et al., 2005b) and spontaneous development of autoim-
mune diseases in mice lacking IL-2Rβ (CD122), which can be
prevented by infusion of donor Tregs (Suzuki et al., 1995; Malek
et al., 2002). Although no single member of this cytokine family
(IL-2, IL-7, or IL-15) is non-redundant in the thymic induction
of tTregs, the most significant defect is observed in IL-2−/− or
CD25−/− animals, in which Foxp3 expression is reduced by 50% in
thymocytes and animals succumb to lethal autoimmune diseases
(Sadlack et al., 1993; Willerford et al., 1995; Fontenot et al., 2005b).
IL-2, the most important γc family member for tTreg induction
(Fontenot et al., 2003; Hori et al., 2003) activates Stat5 through
γc chain-associated Janus Kinase (JAK) 3; pY-Stat5 subsequently
binds to the promoter region of Foxp3 to positively regulate the
gene (Zorn et al., 2006; Burchill et al., 2007; Yao et al., 2007). As
expected, Jak3−/− and Stat5−/− mice have few or no circulating
Foxp3+ cells (Mayack and Berg, 2006; Yao et al., 2007). Of note,
developing Treg-precursors in the thymus are highly attuned to
IL-2 as they express CD25 and thus have a competitive advantage
in the IL-2-poor environment of the thymus. Thus, even subop-
timal IL-2Rβ signaling, for example through mutations of Y→ F
(tyrosine to phenylalanine) at key sites binding Shc or Stat5, is suf-
ficient to support normal tTreg (but not iTreg) development (Yu
et al., 2009; Cheng et al., 2013).
Co-stimulation through CD28 is particularly important for
tTreg development as both CD80/CD86 and CD28 knockout ani-
mals (Salomon et al., 2000; Tai et al., 2005) have striking tTreg
deficiency. Signals transduced through the TCR and CD28 that
are clearly important in thymic Treg lineage commitment include
both the NF-κB and Ras-Raf-MAPK pathways. This is demon-
strated through inhibition of tTreg development by disruptions
to components of either the NF-κB, e.g. Bcl10, PKCθ, CARMA1,
IκB kinase 2, c-Rel, TRAF6 (Schmidt-Supprian et al., 2003, 2004;
Barnes et al., 2009; Isomura et al., 2009; Long et al., 2009; Grigo-
riadis et al., 2011; Shimo et al., 2011; Schuster et al., 2012), or the
Ras-Raf-MAPK pathways, such as RasGRP1 and Raf (Willoughby
et al., 2007; Chen et al., 2008).
In contrast to previous reports suggesting that TGF-β is not
required for the thymic induction of thymocytes (Marie et al.,
2005; Li et al., 2006), conditional ablation of TGF-βRI in double-
positive (CD4+CD8+; DP) thymocytes does result in a temporary
reduction of Foxp3+ thymocytes in neonatal mice (Liu et al.,
2008), suggesting that central Treg selection may be enhanced by
TGF-β signaling. In contrast, Akt signaling in developing thymo-
cytes suppresses Treg development through mTOR (Haxhinasto
et al., 2008), in a manner akin to iTregs (see below).
These observations are consistent with a step-wise model
(Burchill et al., 2008; Lio and Hsieh, 2008) in which Tregs
are selected from late-stage, single-positive (CD4+) thymocytes
(Fontenot et al., 2005a), whose TCRs engage high affinity ligands
(Sakaguchi et al., 2008) presented by either medullary or corti-
cal thymic epithelial cells (mTECs or cTECs) in the context of
MHC class II (Aschenbrenner et al., 2007; Liston et al., 2008b) and
in the presence of CD28 co-stimulation (Tai et al., 2005). Thus,
TCR/CD28 engagement induces expression of CD25 by thymo-
cytes, sensitizing them to IL-2, which instructs Foxp3 and CD25
expression in a Stat5-regulated manner (Burchill et al., 2008; Lio
and Hsieh, 2008). However, there is also some evidence that Tregs
may, in fact, be induced to differentiate at a much earlier, double-
positive (CD4+CD8+), developmental stage before agonist
selection (Pennington et al., 2006). This is consistent with demon-
strations in K14-Aβb mice that, similar to other CD4+ T cells,
positive selection on thymic cortical epithelium is sufficient for
Treg differentiation from DP precursors (Bensinger et al., 2001).
PERIPHERALLY INDUCED TREGS
There is also significant evidence showing that, like other CD4+
lineages, Tregs can be generated from CD4+ naïve precursors
in the periphery. Here, host detection of infection and tissue
injury initiates events that result in recruitment and differenti-
ation of CD4+ T helper (Th) lymphocytes to functions suited to
removal/containment of the noxious stimulus. Specific signaling
pathways essential for differentiation, expression of key TFs, spe-
cific cytokines, and surface molecules distinguish distinct CD4+
Th lineages from each other. Thus, pluripotent naïve CD4+ T
cells (Thp) are induced to “commit” to particular lineages by
mode of stimulation, antigen concentration, co-stimulation, and
cytokine milieu (Constant and Bottomly, 1997) through distinct
pathways, including, but not exclusively, Stat1/Stat4 (Th1), Stat6
(Th2), Stat5 (Treg), and Stat3 (Th17) (Zhu et al., 2010). Each
lineage is then characterized by expression of its own cytokine
profile: IFN-γ (Th1), IL-4 (Th2), and IL-17 (Th17); dominant
TFs: T-bet (Th1), Gata-3 (Th2), Foxp3 (Treg), and Rorc (Th17)
(Zheng and Flavell, 1997; Szabo et al., 2000, 2002; Fontenot et al.,
2003; Wan and Flavell, 2005; Ivanov et al., 2006) and chemokine
receptors: CCR5 and CXCR3 (Th1), CRTH2 and CCR4 (Th2),
and CCR6 (Th17) (Figure 2). Individual lineages are specialized
to promote specific biological functions, for example, immunity
against intracellular microorganisms (Th1), humoral immunity to
control helminthic and other extracellular pathogens (Th2), clear-
ance of extracellular bacteria, and fungi at mucosal surfaces (Th17)
and regulation of immune system activation (Tregs) (Zhou et al.,
2009a; Zhu et al., 2010). Thus, detection of “danger” is a key event
in the initiation of this cascade and recruitment and differentia-
tion of the most appropriate Th lineage(s) is the key determinant
of pathogen removal/persistence and tissue repair/healing during
immune responses.
The conditions favoring peripheral induction of Tregs
(pTregs) include suboptimal dendritic cell (DC) activation,
sub-immunogenic doses of agonist peptide, mucosal admin-
istration of peptide and presence of appropriate cytokines,
notably TGF-β and IL-2 (Chen et al., 2003; Apostolou and von
Boehmer, 2004; Kretschmer et al., 2005; Selvaraj and Geiger, 2007;
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FIGURE 2 | NaïveT helper cell differentiation pathways for lineage
commitment in the periphery. T helper cells (Th) can be induced from
naïve CD4+ cells to differentiate toward Th1, Th2, Th17 and Treg phenotypes
depending on the cytokine milieu present in the environment. Presence of
IFN-γ and IL-12 promote skewing toward Th1 commitment by signaling
through STAT1 and STAT4, respectively. Th1 cells are characterized by
expression ofT-bet, chemokine receptors CCR5 and CXCR3 and produce
IFN-γ, which inhibit Th2 differentiation. Th2 cell commitment is instead
promoted by IL-4 via STAT6 signaling. Th2 committed cells express GATA-3,
chemokine receptors CCR4 and CRTH2 and secrete IL-4, IL-5, and IL-13,
which in turn inhibit Th1 differentiation. Development of both iTreg and Th17
phenotypes requires the presence of TGF-β, but the proinflammatory IL-6
and IL-1 preferentially skews the response toward a Th17 phenotype through
STAT3 signaling leading to the expression of RORC. Th17 cells express the
chemokine receptor CCR6 and secrete IL-17. iTregs are instead induced in
the presence of TGF-β together with IL-2 (and ATRA) through STAT5
signaling, leading to the expression of Foxp3 and can secrete IL-10 and
TGF-β. A definite chemokine receptor for iTregs has not yet been clearly
described. JAK= Janus kinase; STAT=Signal Transducer and Activator of
Transcription. ATRA= all-trans retinoic acid.
Siewert et al., 2008; Zheng et al., 2008). The greater the strength
of the TCR/MHC:peptide interaction and co-stimulation, the
greater the requirement for tolerance-inducing cytokines, specifi-
cally TGF-β and IL-2, to induce a regulatory, as opposed to, effector
phenotype in Thp. Some of this effect is related to the ability of
high concentrations of TGF-β to down-regulate receptors for other
cytokines, including IL-6 (Zheng et al., 2008), and the ability of IL-
2-activated Stat5 to inhibit loci of other lineages (Laurence et al.,
2007), implying that efficient pTreg differentiation is at least par-
tially contingent on inhibition of differentiation to alternate Th
lineages. This assertion is supported by evidence that the presence
of cytokines required for T cell skewing to alternate Th lineages,
such as IL-12 (to Th1) and IL-6 (to Th17) (Figure 2) preferentially
foster development of those lineages in contrast to iTreg through
induction of lineage-specifying Stat proteins and TFs (Wei et al.,
2007).
Of particular note, it appears that not all Thp can differenti-
ate in the periphery to Tregs (Hsieh et al., 2004; Lathrop et al.,
2008). Instead, recent evidence indicates that either the thymus
may remain a site of Treg differentiation during immune responses
(Zelenay et al., 2010) or that recent thymic émigrés are, in fact,
the precursors of pTregs (Paiva et al., 2013). Speculatively, the
implication is that either T cells with certain TCR specificities are
more suited to differentiate into Tregs (presumably due to higher
than average TCR avidity for self-MHC:peptide) or that signals
received by pTreg-precursors in the thymus ensure that the Foxp3
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locus is epigenetically in a state ready for gene transcription in the
periphery. Nevertheless, pTregs suppress antigen driven CD4+ T-
cell expansion and both Th1 and Th2 cytokine production in vitro
in a manner akin to tTregs (Chen et al., 2003); the paucity of distin-
guishing phenotypic and functional characteristics between tTregs
and pTregs is one argument for a high degree of similarity in the
signals required for their induction.
The requirement for low level TCR signaling for induction
of pTregs is highlighted by experiments in which in vivo Foxp3
induction in Thp inversely correlates with the dose of immunogen
(Kretschmer et al., 2005) and in which augmenting TCR signal-
ing by removing an inhibitory E3 ubiquitin ligase (Chiang et al.,
2000) inhibits Foxp3 induction (Wohlfert et al., 2006). Consis-
tent with this, in vitro iTreg induction is inhibited by increasing
concentrations of activating anti-CD3 (Kim and Rudensky, 2006)
whereas premature termination of TCR signaling soon after T
cell activation or inhibition of the PI3 Kinase/Akt/mTOR pathway
downstream of TCR signaling augments iTreg induction (Sauer
et al., 2008). Similarly, while CD28 signaling is critical for cen-
tral selection of Tregs (Salomon et al., 2000), peripheral pTreg
induction is, in contrast, inhibited by strong CD28 ligation (Kim
and Rudensky, 2006; Benson et al., 2007), which explains why
mice deficient in CTLA-4, an inhibitor of T cell activation, have
impaired pTreg induction (Zheng et al., 2006). Similarly, ana-
phylatoxin receptor signaling activates the mTOR pathway; thus
C3ar1−/− or C5ar1−/− mice have impaired mTOR signaling and
take on an iTreg phenotype in response to TGF-β more readily
than wild-type T cells. Antagonism of C3aR and C5aR in human
naïve CD4+ T cells induces functional iTregs (Strainic et al., 2012).
TGF-β directly regulates the Foxp3 gene through both TGF-β-
inducible early gene 1 (TIEG1) and Mothers Against Decapenta-
plegic 3 (Smad3), which bind at promoter and enhancer regions
in the Foxp3 gene to upregulate its expression (Tone et al., 2008;
Venuprasad et al., 2008) (see below). Notch-pathway mediated
signals synergize with TGF-β to enhance Foxp3 expression by
recruiting Notch1, CSL, and Smad proteins to promoter regions of
the Foxp3 gene (Samon et al., 2008). In vivo, DC populations pro-
ducing local TGF-β are clearly sufficient to induce iTregs (Benson
et al., 2007; Yamazaki et al., 2008).
The presence of all-trans retinoic acid (ATRA) in the Thp envi-
ronment synergizes with TGF-β to promote iTreg development;
this effect is sufficient to allow iTreg development even in the
presence of high levels of co-stimulation (Benson et al., 2007).
While receptor-ligand-mediated gene transcription is retinoic acid
receptor (RAR)-α dependent (Elias et al., 2007; Hill et al., 2008),
ATRA promotes iTreg differentiation both directly, through inhi-
bition of differentiation to alternative lineages, notably Th17 (Elias
et al., 2007; Mucida et al., 2007; Xiao et al., 2008), and indirectly,
through the inhibition of environmental cytokines produced by
CD44hi effector memory T cells, especially IL-4 and IFN-γ (Hill
et al., 2008), which support the development of alternative Th
lineages. ATRA, moreover, imprints a gut-homing phenotype on
iTregs (α4β7+CCR9+) (Benson et al., 2007). This is notewor-
thy as CD103+CD11c+ DCs present in lamina propria of small
and large bowel, mesenteric lymph nodes, and Peyer’s patches
induce an identical gut-homing phenotype (Annacker et al., 2005;
Johansson-Lindbom et al., 2005) and the development of iTregs
through secretion of local TGF-β and ATRA (Coombes et al., 2007;
Sun et al., 2007). Such local milieu for the induction of iTregs might
reflect the need to control immune responses directed against anti-
gens expressed by local microbiota and ingested food and may
provide an evolutionary link between iTregs and commensal bacte-
ria. This may explain why several studies have reported a reduction
in lamina propria Tregs of mice housed in germ-free environments
(Strauch et al., 2005; Östman et al., 2006; Ishikawa et al., 2008),
which may be related to the specific organisms that are present or
absent from the “germ-free” environment (Ivanov et al., 2008).
REGULATION OF FOXP3 GENE EXPRESSION
Epigenetic mechanisms, such as DNA methylation, histone
modification, nucleosome positioning, as well as microRNAs
(miRNAs), are essential for control of gene expression (Balti-
more et al., 2008; Wilson et al., 2009; Cedar and Bergman, 2011).
Chromatin remodeling has a role in determining the accessibility
of genes by transcriptional activators or repressors. In particu-
lar, methylated DNA sequences are “silenced”, while opening of
the locus for transcription is linked to demethylation. For com-
prehensive reviews, the reader is referred to (Wilson et al., 2009;
Cedar and Bergman, 2011). Foxp3 gene expression is controlled
by four elements, containing conserved non-coding sequences
(CNS). The first is in the promoter region, two are in the first
intron (CNS1 and CNS2, at 2 and 4.5 kb downstream of the tran-
scriptional start site (TSS) of murine Foxp3, respectively) and the
fourth (CNS3, at 7 kb downstream of the TSS of murine Foxp3) is
in the second intron. These sites are regulated by epigenetic modifi-
cations that determine chromatin structure and DNA methylation,
altering the accessibility of the gene locus to TFs. Known TF
binding and epigenetic modifications at these sites are shown in
Figure 3.
Three important caveats should be noted here. The first is
that emerging evidence suggests a role for Foxp3 binding within
enhancer elements in the Foxp3 gene, exploiting enhancers “estab-
lished” by Foxp3 predecessors, such as Foxo1 (Samstein et al.,
2012). These data are not included in Figure 3. The second is that
Foxp3 expression alone is insufficient for establishment of the Treg
lineage; rather, the development of a Treg-specific genome-wide
methylation pattern (“nTreg-Me”) in addition to Foxp3 expression
is critical (Ohkura et al., 2012). Thus, nTreg-Me is independent
of Foxp3 expression, but necessary for Foxp3+ cells to acquire
the genome-wide transcriptional profile, stability, and functional
characteristics of the Treg lineage (suppressive capability) (Ohkura
et al., 2012). Interestingly, in vitro induced iTregs lack the nTreg-
Me pattern, whilst in vivo generated iTreg gradually develop it after
TCR stimulation (Ohkura et al., 2012). This difference in stabil-
ity of Foxp3 expression between tTregs and iTregs could then be
attributed to epigenetic differences at the Foxp3 locus, as detailed
below. The third, as has been elegantly described recently in the
mouse, is that differentiation of both tTregs and iTregs is criti-
cally dependent on transcriptional repression of alternate lineages
through the expression of the Bach2 TF (Roychoudhuri et al.,
2013). Thus, animals deficient in this TF are unable to generate
Tregs and succumb to spontaneous autoimmune disease (Roy-
choudhuri et al., 2013). Interestingly, this TF is also linked to
multiple autoimmune diseases in man.
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FIGURE 3 |The Foxp3 epigenome and transcription factor binding
sites. Four distinct regions of the Foxp3 gene are susceptible to
epigenetic modification. These are the Foxp3 promoter and three other
conserved non-coding sequences (CNS): CNS1 – the TGF-β
sensor/enhancer, CNS2 – Treg-cell-specific demethylation region (TSDR),
and CNS3 – a Foxp3 pioneer element. Epigenetic modifications include
histone acetylation/deacetylation and CpG methylation/demethylation
and are shown at each locus. Known transcription factor binding sites
and the signals required for access to each region are also shown.
STAT5= signal transducer and activator of transcription 5,
SMAD3= small body size mothers against decapentaplegic 3,
CREB= cAMP-response-element binding protein, ATF= activating
transcription factor, NFAT=nuclear factor of activated T cells,
AP1= activator protein 1 (a dimer of FOS and JUN),
TIEG1=TGF-β-inducible early gene 1; Ets=E-twenty six; RAR= retinoic
acid receptor; ATRA= all-trans retinoic acid; Foxo= forkhead box o.
Foxp3 promoter
CpG motifs in the Foxp3 promoter are basally demethylated in
resting Tregs, but partially methylated in conventional naïve CD4+
T cells (Kim and Leonard, 2007; Janson et al., 2008). In addition,
histones in this region are more highly acetylated in Tregs than in
naïve T cells (Mantel et al., 2006; Kim and Leonard, 2007). As a
result, the Foxp3 promoter is more accessible for the binding of
TFs, such as NFAT, AP1, STAT5, TIEG1, and Ets1 and 2 [recently
described to bind the Foxp3 promoter (Fayyad-Kazan et al., 2010)]
in Tregs than in conventional T cells. In mice, the Foxp3 promoter
in conventional T cells remains methylated following TCR activa-
tion, albeit at a lower level than at baseline (Janson et al., 2008), and
demethylation requires activation in the presence of TGF-β (Kim
and Leonard, 2007; Janson et al., 2008); these structural effects
limit and promote access for induction of Foxp3 transcription
respectively.
CNS1 (TGF-β-sensitive enhancer element)
CNS1, an “enhancer” region in the Foxp3 locus, contains bind-
ing sites for NFAT and Smad3 and is in an accessible, histone-
acetylated, state in both tTregs and iTregs (Tone et al., 2008) but not
in naïve, resting T cells. This area has no CpG motifs, therefore the
sole epigenetic modification at this locus is through histone acety-
lation. RAR and RXR (retinoid X receptor) bind within CNS1
and are responsible for increased histone acetylation, permitting
greater Smad3 binding (Xu et al., 2010), thus, explaining some
of the direct effects of ATRA in iTreg induction. CNS1 knock-
out animals demonstrate normal tTreg development, but have
impaired iTreg induction (Zheng et al., 2010); therefore, CNS1
is redundant in thymic Treg selection, but is essential for periph-
eral induction of Tregs, consistent with the role of TGF-β in pTreg
generation.
CNS2 (“Treg-specific demethylated region”, TSDR)
A third, highly conserved, CpG dinucleotide-rich region in both
mouse and human Th cells, termed the “Treg-specific demethy-
lated region” (TSDR), is completely demethylated in nTregs, but
methylated in conventional T cells (Baron et al., 2007; Floess et al.,
2007). In tTregs, this area also contains acetylated histones (H3Ac
and H4Ac) (Floess et al., 2007) and TF binding sites, which in
the demethylated state bind Stat5, CREB/ATF (Yao et al., 2007;
Nagar et al., 2008), Foxo1, and Foxo3 (Ouyang et al., 2010), which
also bind the Foxp3 promoter (Harada et al., 2010; Ouyang et al.,
2010). Interestingly, Foxp3 induction by TGF-β is associated with
only partial demethylation of the TSDR, an unstable state that
reverses upon restimulation (Floess et al., 2007). Thus, iTregs con-
tain methylated CpGs. The TSDR was initially described as having
enhancer activity (Kim and Leonard, 2007). However, given quan-
titatively similar Foxp3 expression in iTregs and tTregs despite
large differences in methylation state at the TSDR, it is unlikely
that it acts as an enhancer element; instead, TSDR demethylation
appears critical for stable Foxp3 expression (Floess et al., 2007;
Nagar et al., 2008; Polansky et al., 2008). Indeed, pharmacological
inhibition of DNA methyltransferase-1 (Dnmt-1) in conventional
T cells, using the covalent inhibitor 5-azacytidine (5AzadC), fol-
lowed by activation through the TCR, results in stable expression
of Foxp3, in contrast to the transient Foxp3 expression seen with
TCR activation alone (Kim and Leonard, 2007; Nagar et al., 2008;
Polansky et al., 2008; Josefowicz et al., 2009). Similarly, CNS2-
deficient animals have reduced Treg numbers only after 6 months
of age (Zheng et al., 2010), suggesting that CNS2 is redundant
for expression of Foxp3 but critical for its stable maintenance. Of
note, demethylated CNS2 acts as a binding site for Foxp3 in a
Runx1- and Cbf-β-dependent manner (Zheng et al., 2010), which
may serve as a mechanism for stable Foxp3 expression in mature
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Tregs. The signals controlling methylation/demethylation at the
TSDR are currently unknown, but given the difference between
iTregs and tTregs in Foxp3 stability, it is likely that demethylation
at this locus is thymically initiated.
CNS3 (Pioneer element)
CNS3 contains a DNase I hypersensitive site and is bound by c-
Rel, IκBNS, and p50, members of the NF-κB family (Zheng et al.,
2010; Schuster et al., 2012). Chromatin modifications at this site
show permissive marks (H3K9/14Ac, H3K4me2, and H3K4me1)
in Tregs, but also mono (H3K4me1) and di-(H3K4me2) methy-
lation in Treg-precursors (CD4+CD8+ and CD4+CD8- thymo-
cytes) (Zheng et al., 2010). As permissive marks are absent at
CNS1 and 2 in Treg-precursors, this argues that CNS3 can bind
TFs before both CNS1 and 2 during Treg induction and opens the
Foxp3 locus to other TFs, thus acting as a pioneer element (Zheng
et al., 2010). Indeed, CNS3−/− mice have significantly reduced
Treg numbers, but normal per cell levels of Foxp3 in the remain-
ing Tregs, supporting the assertion that CNS3 acts as a pioneer
element. The importance of c-Rel binding is highlighted by the
profound loss of Tregs seen in mice that are c-Rel deficient (Ruan
et al., 2009; Zheng et al., 2010). It is possible that the binding of c-
Rel acts as a chromatin opener or, that c-Rel, in co-operation with
other TFs, e.g., p65, NFAT, CREB, and Smad3, enhances formation
of an enhanceosome at the Foxp3 promoter (Ruan et al., 2009).
DISTINGUISHING tTREGS FROM iTREGS
To date, no single marker has been identified to differentiate tTregs
from iTregs and no definitive test to distinguish their in vivo
functions. The Treg transcriptional profile is dominated by genes
induced by cell activation alone (Hill et al., 2007) and has so far not
yielded definitive markers to distinguish iTregs from tTregs despite
early promise (Gavin et al., 2007; Zheng et al., 2007). Reports that
tTregs exclusively express Helios, an Ikaros transcription factory
family member (Thornton et al., 2010), have been challenged by
the demonstration that Helios is induced during T cell activation
and proliferation and then down-regulated (Akimova et al., 2011).
Thus, expression of Helios cannot reliably differentiate iTregs from
tTregs. Likewise, although TSDR demethylation could in theory
distinguish Tregs that have received thymic induction from those
induced in the periphery, in vivo generated iTregs can also effi-
ciently demethylate the TSDR if given sufficient time (in this
case, 6 weeks) (Polansky et al., 2008). Very recently, neuropilin-
1 (Nrp-1) has been described by two groups as differentially
expressed in murine tTregs and pTregs, being poorly expressed
in the latter (Weiss et al., 2012; Yadav et al., 2012). Nrp-1 is a cell
surface molecule mediating prolonged interactions between Tregs
and DCs (Sarris et al., 2008), a receptor for TGF-β (Glinka and
Prud’Homme, 2008) and vascular endothelial growth factor (Fer-
rara et al., 2003), which has previously been proposed as a Treg
marker (Bruder et al., 2004; Hansen et al., 2012). Of interest, the
lowest Nrp-1 expression was seen in in vivo generated pTregs com-
pared to in vitro generated iTregs, presumably reflecting positive
regulation of Nrp-1 by high dose TGF-β in vitro (Weiss et al., 2012).
These observations have not yet been replicated in human Tregs,
although Nrp-1+ Tregs have been identified in inflamed synovial
fluid of patients with rheumatoid arthritis (E et al., 2012).
tTREG AND iTREG FUNCTION
Tregs suppress target cells through a number of inhibitory mech-
anisms, including cell–cell contact-dependent inhibition (Taka-
hashi et al., 1998; Thornton and Shevach, 1998; Ng et al., 2001),
secretion of inhibitory cytokines (Powrie et al., 1996; Asseman
et al., 1999; Belkaid et al., 2002; Maloy et al., 2003; Collison et al.,
2007), cytolysis of target cells (Gondek et al., 2005; Cao et al., 2007),
metabolic disruption (Deaglio et al., 2007), modulation of APC
function (DiPaolo et al., 2007; Puccetti and Grohmann, 2007),
and competition for environmental IL-2 (Pandiyan et al., 2007).
Such redundancy suggests that the mode of suppression may be
context dependent and directed by the degree and mode of inflam-
mation. While details of these mechanisms falls outside the scope
of this review, it is noteworthy that they are not mutually exclusive,
and while not necessarily limited to a single “delivery system”, are
mostly compatible with a cell-to-cell contact deployment pack-
age. For example, Tregs can deliver suppressive factors like cyclic
adenosine monophosphate (cAMP) into conventional T-cells via
gap junctions (Bopp et al., 2007), they can modulate APC func-
tion through membrane-bound suppressive TGF-β (Nakamura
et al., 2001), through negative signaling by cytotoxic T-lymphocyte
antigen-4 (CTLA-4) (Read et al., 2006) or lymphocyte-activation
gene 3 (LAG3) (Huang et al., 2004).
So far, no distinct functional differences have been conclu-
sively demonstrated between tTregs and iTregs, suggesting that
the mechanistic repertoire of Treg function is specified by lin-
eage and not mode of induction. Indeed, iTregs are as potent
as tTregs in protecting from autoimmune diseases by prevent-
ing the antigen-presenting capacity of DCs to autoreactive Teffs
(DiPaolo et al., 2007). As only a small proportion of the tran-
scriptional profile of Tregs can be explained by expression of
Foxp3, and the majority by T cell activation and survival sig-
nals (Hill et al., 2007), it is not surprising perhaps that function
is also lineage and not induction-specific. As argued above, it
is generally accepted that tTregs function to prevent the devel-
opment of autoimmune diseases and that iTregs limit inflam-
mation to neo-antigens, such as bowel commensal. iTregs can
clearly be generated and are essential and sufficient to mediate
oral tolerance in response to dietary antigens in animals devoid
of tTregs (Mucida et al., 2005; Curotto de Lafaille et al., 2008).
Although these experiments have been conducted under highly
non-physiological conditions, the same mechanisms of iTreg
induction in the periphery may explain the persistence of alterna-
tive neo-antigens, such as pathogenic organisms (Robertson and
Hasenkrug, 2006; Wohlfert and Belkaid, 2008) or neoplastic cells
(Zou, 2006).
TREG PLASTICITY
Emerging concepts of mammalian Th cell polarization have
recently challenged traditional models of terminal differentiation,
suggesting that Th lineage commitment is not as irreversible as
previously thought and that lineage reprograming to alternate
lineages can be achieved through the expression of key TFs and
appropriate epigenetic modifications in lineage-specifying genes.
For in-depth reviews, please see (O’Shea and Paul, 2010; Hira-
hara et al., 2011; Nakayamada et al., 2012). Several reports in the
literature suggest that Tregs retain significant plasticity, with the
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capacity to express TFs and signature cytokines, particularly, of
Th1 (Koch et al., 2009) and Th17 (Koenen et al., 2008; Beriou
et al., 2009; Afzali et al., 2010) cells.
The ability of Tregs to express key TFs of alternate lineages
may license them to efficiently regulate inflammation generated
by those Th lineages. For example, T-bet expression by Tregs
induces CXCR3 expression, licensing Treg trafficking to sites of
Th1-mediated inflammation to control Th1 cells (Koch et al.,
2009). Likewise, expression of IFN-γ by Tregs may be a surro-
gate marker for T-bet expression and licensing for suppression of
Th1 inflammation (Feng et al., 2011). Expression of interferon reg-
ulatory factor-4 (IRF4), a TF essential for Th2 (Rengarajan et al.,
2002) and Th17 (Brüstle et al., 2007) cell differentiation directs
Tregs to selectively regulate Th2 responses (Zheng et al., 2009).
Selective ablation of Stat3, critically required for Th17 differentia-
tion (Figure 2), in Tregs results in uncontrolled Th17-dependent
responses (Chaudhry et al., 2009).
On the other hand, plasticity in Tregs may indicate a potential to
assume an effector phenotype and to contribute to inflammation
(Zhou et al., 2009b). In particular, as Treg and Th17 differentiation
from naïve Thp are reciprocally linked (Bettelli et al., 2006; Mangan
et al., 2006;Veldhoen et al., 2006; De Jong et al., 2010) (see Figure 2)
and the two lineages have opposing functions (Afzali et al., 2007),
lineage reprograming from one to the other could have signifi-
cant implications for the development of autoimmune diseases
and for programs of Treg-based cell therapy in humans. It is cer-
tainly possible that there may be a threshold of expression and/or
activation of Th-specific TFs in Foxp3+ Tregs allowing them to
act either as lineage-specific regulators or contributors to effector
responses. There remains still considerable controversy regard-
ing Treg plasticity and lineage reprograming as even complex,
and elegant, fate-mapping murine models (Zhou et al., 2009b;
Hori, 2010, 2011; Rubtsov et al., 2010) have produced divergent
results.
Mechanistically, the epigenome of many “terminally differen-
tiated” Th cells shows considerable flexibility in accessibility of
genes of alternate lineages to TFs. This is elegantly described in
the study of Wei et al. (2009) showing a rather flexible signa-
ture of genome-wide H3K4me3 and H3K27me3 maps of naïve,
Th1, Th2, Th17, iTreg, and tTreg cells. In this study, the methy-
lation of loci for signature cytokines conformed broadly to that
expected from lineage commitment; however, the epigenome of
“master” TFs showed significant flexibility, presenting both per-
missive and repressive modifications in the various Th subsets,
including bivalent epigenetic states. This suggests that the overall
balance of epigenetic state determines cell differentiation and that
bivalent modifications might allow specific lineage regulator gene
loci to be activated under different polarizing conditions, thus
reprograming Th cells into other lineages. For example, tTregs and
iTregs both have repressive H3K27me3 marks at the Il17a locus.
This is in contrast to permissive H3K4me3 at the Rorc locus in
iTregs and bivalent chromatin at this locus in tTregs (Wei et al.,
2009), potentially permitting co-expression of Foxp3 and RORγt
after culture under Th17 polarizing conditions (Xu et al., 2007;
Yang et al., 2008). Signals from the micro-environment are then
clearly key to lineage stability. While much focus has been on the
local cytokine cytokine milieu, recent data has also highlighted the
role of local complement components, notably the anaphylatoxins
C3a and C5a, which can signal through cognate receptors on Tregs
to down-regulate Foxp3 expression by activating Akt (Kwan et al.,
2013).
Given the difficulty in distinguishing pTregs from tTreg in a
healthy host, no definitive experiment has yet conclusively shown
a difference in Th17 plasticity between tTregs and iTregs in vivo
(Zhou et al., 2009b). Human data is also inconclusive; while
it appears that Th17 plasticity is restricted to a population of
suppressive memory Tregs expressing the lectin receptor CD161
(Afzali et al., 2013; Pesenacker et al., 2013), divergent reports
suggest that these cells are thymically derived (predominantly
demethylated TSDR, Pesenacker et al., 2013) and peripherally
induced [low Helios expression, virtual absence from umbilical
cord blood and CD45RA- phenotype (Ayyoub et al., 2009; Afzali
et al., 2013)].
miRNA AND TREGS
Gene transcription events are also heavily influenced by micro-
RNAs (miRNAs or miRs) and recent evidence supports the role of
this class of molecules in Treg biology. miRNAs are an evolution-
arily conserved class of pleiotropically acting small endogenous
RNAs, about 23 nucleotides long, that play important gene-
regulatory roles by pairing to the mRNAs of protein-coding genes
to direct their post-transcriptional repression. miRNAs are pre-
dominantly transcribed by RNA polymerase II, which produces a
primary transcript containing the mature miRNA sequence and a
varying amount of flanking region (Lee et al., 2004). Two nucle-
ases then process the miRNA: the first one, Drosha, cleaves the
primary miRNA into a precursor miRNA (Han et al., 2006) that
is exported from the nucleus by exportin 5 (Yi et al., 2003);
after reaching the cytoplasm, the precursor miRNA is further
processed by the other nuclease, Dicer, and is loaded into the
RNA-induced silencing complex (RISC) (Chendrimada et al.,
2007). Finally, a specific single strand of the miRNA duplex is
selected as a guide to direct sequence-specific targeting of mRNA
3’ untranslated regions (UTRs) by RISC (Bartel, 2009). In mam-
malian cells, miRNAs silence genes mainly through binding of
target mRNA leading to degradation of the mRNA; however,
another mechanism of repression at a translational level has
been reported, showing that miRNAs can inhibit either the ini-
tiation or the elongation stages of protein translation (reviewed
in Pillai et al., 2007; Lodish et al., 2008). Interestingly, given the
short sequence and non-stringent binding to target sequence,
abiding to a Watson–Crick match, an individual miRNA is capa-
ble of regulating dozens of distinct mRNAs (Bartel, 2009). For
a general review on miRNAs, please see (Chen and Rajewsky,
2007).
MicroRNAs have been implicated as fundamental regulators
of post-transcriptional programs and play a role in T-lymphocyte
development, differentiation, and effector functions since they are
differentially expressed, both spatially and temporally, in many
types of immune cells (Lykken and Li, 2010). MicroRNA appear
critical for the Treg phenotype, as conditional knockout of Dicer
in CD4 cells (CD4CreDicer∆/∆ animals) results in substantial deple-
tion of tTregs and inhibits induction of Foxp3 in naïve CD4 T-cells
by TGF-β (Cobb et al., 2006). These mice develop spontaneous
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autoimmune disease from about 3–4 months of age, in contrast to
conditional knockout of Dicer in Foxp3+ cells (Foxp3CreDicerfl/fl),
which results in spontaneous autoimmune disease that is fatal
by 4 weeks of age (Liston et al., 2008a; Zhou et al., 2008b). In
the latter model, Foxp3 expression is unstable and Tregs revert
to an effector phenotype producing IL-4 and IFN-γ as part of
the disease (Zhou et al., 2008b). Likewise, conditional disrup-
tion of Drosha in CD4 cells produces a very similar phenotype
(Chong et al., 2008). Dicer and Drosha knockout, however, results
in ablation of not only canonical miRNAs, but also that of other
small cellular RNA species (e.g., siRNAs and shRNAs). That the
phenotype of mice with ablated Dgcr8, an RNA-binding protein
required in the processing of canonical miRNAs (Babiarz et al.,
2008), resembles that of the Dicer deficient mice (Jeker et al.,
2013) establishes that miRNAs are critical for normal Treg devel-
opment in the thymus and the periphery and they are essential
for normal Treg function. Conversely, Foxp3 also contributes to
the miRNA signature of Tregs (Cobb et al., 2006; Rouas et al.,
2009).
Of the miRNAs that are important for Treg function, only a
few are known and the exact function(s) of these are still largely
unknown. As a single miRNA can regulate potentially thousands
of genes, small differences in miRNA profiles can have profound
effects on T cell function. The miRNA machinery and miRNAs
that are differentially expressed in Tregs, including those known
to be direct Foxp3 targets are shown in Figure 4.
Amongst these, miR-31 is under-expressed in human Tregs
while miR-21 is over-expressed in both human and mouse Tregs.
Using lentiviral transduction studies, it can readily be seen that
miR-31 and miR-21 have opposing effects on FOXP3/Foxp3
expression. Whilst miR-31 negatively regulates FOXP3 (it has
a direct binding site in the 3′UTR of FOXP3 mRNA), mir-21
positively regulates FOXP3/Foxp3 in an indirect, but still not
fully elucidated, manner (Rouas et al., 2009). Of interest, his-
tone deacetylase inhibition using valproate reduces miR-31 and
increases mir-21 as well as FOXP3 expression in human Teffs to
levels seen in Tregs (Fayyad-Kazan et al., 2010). This change in
miRNA profile is independent of the change in FOXP3 expression
(Fayyad-Kazan et al., 2010).
MicroRNA-155, which has previously been studied in T and B
cell biology (Baltimore et al., 2008), is a direct Foxp3 target (Mar-
son et al., 2007; Zheng et al., 2007; Liston et al., 2008a), and highly
expressed in Tregs. Mir-155 targets suppressor of cytokine signal-
ing 1 (Socs1), enhancing Stat5 signaling. As a result, deletion of
miR-155 results in limited Stat5 signaling, attenuating IL-2 signal-
ing, manifesting as reduced thymic and peripheral Treg numbers
(Lu et al., 2009). It may also target Foxo3a, albeit in a Treg cell line
(Yamamoto et al., 2011).
Mir-146a is another microRNA prevalently expressed in Tregs
that targets Stat1; deletion of mir-146a in Tregs causes a severe
autoimmune phenotype akin to Dicer knockout animals, charac-
terized by increased numbers of poorly functional Foxp3+ Tregs
in the periphery (Lu et al., 2010). As thymic Treg numbers are
unaltered, it is likely that the biological role of mir-146a is preferen-
tially to regulate Treg gene expression in the periphery. Indeed, not
only do miR-146a−/− Tregs fail to control Teffs in the periphery,
but they also gain Th1-like properties, such as secretion of IFN-γ
(Lu et al., 2010), as a result of failure to regulate Stat1 signaling
(Tang et al., 2009; Lu et al., 2010).
None of miR-21, miR-31, miR-155 nor miR-146a have been
shown to regulate gene expression preferentially in tTregs com-
pared to iTregs or vice versa. Mir-10a, on the other hand, is
preferentially expressed in tTregs, but poorly expressed in iTregs
induced with TGF-β without ATRA (Jeker et al., 2012; Takahashi
et al., 2012). Of note, expression of miR-10a is lowest in Tregs
from animals prone to autoimmune disease, such as non-obese
diabetic (NOD) mice, and in Tregs with unstable Foxp3 expression
(Jeker et al., 2012). miR-10a expression in Tregs that lose Foxp3
expression is the same as in Teffs (Jeker et al., 2012). miR-10a
is functionally linked to stabilization of Foxp3 expression (Jeker
et al., 2012) and targets the transcriptional repressor Bcl-6 and
corepressor Ncor2 to limit conversion of iTregs to Tfh (Takahashi
et al., 2012). It also fine-tunes Thp fate decisions between iTreg
and Th17 (Takahashi et al., 2012).
Thus, these studies show a defined requirement of miRNAs for
the differentiation and suppressive function of Treg cells as well as
their lineage stability. Differential expression of miRNAs in tTregs
and iTregs could reflect divergent pathways of differentiation,
functional properties or lineage stability.
OTHER, FOXP3−, T CELLS WITH REGULATORY FUNCTION
In addition to Tregs, a number of other inducible T cells have
been described with regulatory properties. These include mem-
bers of the CD4+ (Th3, Tr1, and iTr35) and CD8+ (CD8+CD28−)
families. Amongst these, one of the most controversial is the T
helper 3 (Th3) subset. This subset was described as an unusual
Th2-like regulatory subset, which secretes TGF-β, derived from
orally tolerized animals induced by mucosal stimulation with
antigen (Chen et al., 1994). Thus, Th3 cells could be induced
through cognate stimulation of CD4+ Thp by APC together with
CD86 co-stimulation, particularly in the presence of TGF-β and
IL-4 (Inobe et al., 1998; Seder et al., 1998; Weiner, 2001). Fur-
ther growth and division of Th3 cells was dependent on IL-4
and TGF-β rather than IL-2, and some Th3 clones produced
IL-4 and/or IL-10 together with TGF-β. Th3-mediated suppres-
sion, for the maintenance of oral tolerance, was described as
mediated by TGF-β, secreted in response to CTLA-4 ligation
(Chen et al., 1998). There is, thus, a degree of similarity between
Th3 cells and iTregs given their peripheral (TGF-β-enhanced)
induction, mucosal location and TGF-β-dependent function.
The lack of iTreg- or Th3-specific markers effectively ensures
that the two populations cannot at present be distinguished as
disparate.
Type 1 regulatory T cells (Tr1) cells are Foxp3- regulatory
T cells that are induced in the periphery in a TCR-dependent
and antigen-specific manner through either repeated stimulation
with antigen or encounter of antigen in the context of imma-
ture DCs (Jonuleit et al., 2000; Dhodapkar et al., 2001) or IL-10
(Groux et al., 1997), with or without IFN-α (Levings et al., 2001).
Thus, potent Tr1 induction can be achieved through stimulation
of human T cells with a subset of IL-10 producing tolerogenic
DCs (DC-10) (Gregori et al., 2010). IL-10 produced by DC-10
stimulates HLA-G expression on target Thp; HLA-G subsequently
binds ILT4 (immunoglobulin-like transcript 4) on the DC-10 to
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FIGURE 4 |The miRNA machinery and miRNAs differentially
expressed inTregs compared to other CD4+ T cells. Shown on the left
(A) are specific miRNAs that are over (arrow pointing up) or under (arrow
pointing down)-expressed in Tregs compared to other Th cells. miRNAs
that are over-expressed (miR-374, miR-181c) or under-expressed
(miR-125a) without a known target or function in Tregs are indicated with a
question mark. Some miRNAs are induced by Foxp3, leading to either
down-regulation of a specific target (e.g., miR-155 repressing SOCS1) or
inducing positive feedback on Foxp3 expression (miR-10a, in combination
with ATRA and TGF-β). miR-21 is also an indirect positive regulator of
Foxp3, but its mechanism of action is still unknown. Shown on the right
(B) is the miRNA processing and targeting machinery, depicting miR-31,
an under-expressed microRNA in Tregs, which targets the 3′ UTR of Foxp3
mRNA. The primary miRNA transcript is first processed in the nucleus by
Drosha. The precursor is then exported from the nucleus by Exportin 5 and
in the cytoplasm a second nuclease, Dicer, generates a double stranded
miRNA. The functional strand is subsequently selectively loaded onto
RISC. Binding of the mature miRNA to the 3′ UTRs of the target mRNA
leads to its degradation. JAK= Janus kinase; STAT=Signal Transducer and
Activator of Transcription; SOCS= suppressor of cytokine signaling
proteins; RISC=RNA-induced silencing complex (RISC);
UTR=untranslated region.
augment Tr1 induction (Gregori et al., 2010). Intriguingly, engage-
ment of complement receptor CD46 induces IL-10 producing
T-cells phenotypically similar to Tr1 cells (Kemper et al., 2003).
Since such complement engagement occurs in vivo (Le Friec et al.,
2012) and in vitro (Cardone et al., 2010) to induce Th1 cells before
switch to a Tr1 phenotype, an interesting possibility remains that
a “Tr1 phenotype” could also represent a final common pathway
of activated T cells that have gone through an inflammatory phase
and have entered a self-regulatory, IL-10 producing,phase required
for wound healing and tissue repair. Indeed, this would comply
with the fact that Th1 cells, Th2 cells, and Th17 can all produce
IL-10, as is further discussed in an accompanying article in this
series. Interestingly, ATRA inhibits IL-10 production, in contrast
to augmentation of Foxp3 (Maynard et al., 2009); thus it is pos-
sible that induction of Tr1 cells and iTreg in an ATRA-containing
environment are to an extent mutually exclusive.
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Tr1 cells are anergic, proliferate poorly to antigen, produce little
IL-2 or IL-4, but suppress through production of IL-10 and TGF-β
(Groux et al., 1997). In addition, they secrete IFN-γ and IL-5; thus
their cytokine profile is distinct from Th1, Th2 and classical Tregs
(Groux et al., 1997). Although they do not constitutively express
Foxp3 (Vieira et al., 2004), and can be generated in FOXP3 mutant
patients with IPEX syndrome (Passerini et al., 2011), they are able
to mediate their suppressive function through multiple mecha-
nisms, such as engagement of CTLA-4 and Programed cell death 1
(PD1) (Akdis et al., 2004; Meiler et al., 2008), metabolic disruption
through CD39 and CD73 (Mandapathil et al., 2010), and cytolysis
of APCs through release of granzyme B and perforin (Magnani
et al., 2011). Thus, they share functions in common with Foxp3+
Tregs. Until now, no reliable markers could successfully distin-
guish Tr1 cells from other IL-10 producing T cells. However, the
recent description of co-expression of integrin α-subunit CD49b
and lymphocyte-activation gene (LAG)-3 as identifiers of human
and mouse Tr1 cells (Gagliani et al., 2013), will allow further spe-
cific characterization of Tr1 cell genesis and function as well as its
relation to other IL-10 producing T cells.
IL-35 is a member of the IL-12 cytokine family (Figure 5) with
inhibitory functions. It was originally described in murine cells
as a heterodimeric suppressive cytokine secreted from Foxp3+
Tregs [the Ebi gene is a downstream target of Foxp3 (Collison
et al., 2007)], without which the suppressive function of Tregs
was significantly reduced, rendering Tregs incapable of control-
ling experimental inflammatory bowel disease (Collison et al.,
2007). Secretion of IL-35 by Tregs is increased by co-culture
with Teffs, subsequently enabling them to suppress Teffs sepa-
rated by a semi-permeable membrane (Collison et al., 2009). In
both man and mouse, IL-35 can induce the development of T cells
that secrete IL-35, but not TGF-β or IL-10, and can then medi-
ate suppression in an IL-35-dependent manner. These induced
regulatory T cells have been termed iTr35 (Collison et al., 2010;
Chaturvedi et al., 2011). iTr35 cells are hyporesponsive to restim-
ulation and, like Tr1 cells (see below), don’t express the TF Foxp3.
Moreover, they can be induced from Foxp3−/− murine Thp (Col-
lison et al., 2010), showing that Foxp3 is neither required for their
induction nor for their function. Of note, however, iTr35 cells
have a gene transcriptional profile that is very similar to non-
suppressive Teffs activated without IL-35 (though very different to
Tregs) (Collison et al., 2010), suggesting that the induction of iTr35
cells, as with iTregs, is dominated by signals that are generic to T
cell activation/survival and requires only modest transcriptional
changes induced by IL-35. Although the exact role of IL-35 and
iTr35 cells in immune physiology is not known, ectopic expression
of IL-35 on pancreatic β-cells can protect against experimental
autoimmune diabetes (Bettini et al., 2012) and can be expressed
by other immune cells, such as CD8+CTLA-4+ T cells that can
suppress tumor (prostate)-specific Teff responses (Olson et al.,
2012). The induction of iTr35 cells by neighboring cells producing
IL-35, such as Foxp3+ Tregs, may be important in providing at
least partial explanations for the phenomenon of infectious toler-
ance (Waldmann et al., 2006), which hypothetically could be a key
component in the success or failure of Treg-based programs of cell
therapy.
Briefly, T-lymphocytes with regulatory functions are not only
limited to the CD4+ population, but include some CD8+ popula-
tions as well. Gilliet and Liu, for instance, demonstrated that stim-
ulation of naïve CD8+ T-cells with CD40 ligand-activated plasma-
cytoid DCs induced, in an IL-10-dependent manner, poorly pro-
liferative CD8+ T-cells. These cells produced significant amounts
of IL-10, low IFN-γ, no IL-4, IL-5, nor TGF-β, and suppressed
CD8+ alloresponses through IL-10 (Gilliet and Liu, 2002). Like-
wise, repeated stimulation of CD8+ T cells with antigen can
generate suppressive CD8+CD28− T cells (Jiang et al., 1998) that
FIGURE 5 | IL-12 family of cytokines. Members of the structurally related
IL-12 family of cytokines all comprise of a helical subunit (depicted as blue
ovals) and a cytokine receptor homology domain (depicted as orange
rectangles) with or without an intervening immunoglobulin-like domain (red
semi-circles). Thus far, four family members have been identified: IL-12, IL-23,
IL-27, and IL-35. Ebi3=Epstein–Barr-Virus-induced molecule 1.
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show significant overlap in molecular signature with Tregs (Foxp3,
GITR, CTLA-4, CD25 for example) (Scotto et al., 2004). The loss
of CD28 on CD8 cells, through repeated stimulation, is a well
recognized phenomenon and occurs physiologically during aging
(Weng et al., 2009) and correlates with poorer responses to vaccina-
tion (Saurwein-Teissl et al., 2002). These cells may have a variety of
suppressive mechanisms that include inhibition of co-stimulatory
molecules on T cells (Ciubotariu et al., 1998) or DCs (Li et al.,
1999).
CELL-BASED THERAPY USING TREGS
The critical role played by Tregs in maintaining peripheral tol-
erance to self-antigens, thereby controlling autoimmune diseases,
reveals the clinical potential of these cells, which can find extensive
application to induce transplant tolerance (Wood and Sakaguchi,
2003; Hippen et al., 2011; Issa et al., 2011; Lombardi et al., 2011;
Blazar et al., 2012; Tang et al., 2012). In this context, emerging
data from animal models reveals that adoptive transfer of Tregs
could ameliorate autoimmune diseases, graft-versus-host disease
(GvHD) (Blazar et al., 2012) and also induce tolerance to solid
organ transplants (Issa et al., 2011). These findings suggest that
clinical therapy with human Tregs represents a promising strat-
egy for treatment of autoimmune diseases or for induction of
transplantation tolerance.
In solid organ transplant recipients, allo-reactive Teffs in the
immune repertoire outnumber Tregs, causing inflammation and
leading to graft rejection. So far, most, if not all, therapies aimed
at preventing transplant rejection have targeted Teffs. However,
another approach, artificially increasing Treg number to regulate
Teffs (Figure 1), also has the potential to promote tolerance and
facilitate graft survival (Safinia et al., 2013). This is supported by
evidence showing that prolonged organ engraftment is essential to
induce and expand allo-antigen-specific Tregs, favoring long-term
acceptance (Hamano et al., 1996) and data that show better trans-
plant outcomes when organs are infiltrated with greater numbers
of Tregs.
There are effectively three strategies for using Tregs as ther-
apeutic agents in humans. The first is introduction of freshly
isolated donor Tregs into lymphopaenic hosts, an approach most
attractive in the prevention of GvHD post-bone marrow trans-
plantation (Di Ianni et al., 2011). The lymphopaenic environment
supports expansion of infused Tregs in vivo and does not cause
over-immunosuppression. Indeed, similar experiments in mice
have shown that the animals are immunologically intact and
able to respond to vaccination (Gaidot et al., 2011) and to con-
trol influenza virus infections (Bushell et al., 2005) using this
approach.
The second approach involves the in vitro expansion of Tregs
prior to infusion, a pre-requisite for infusion of large numbers
of Tregs, since their numbers in the peripheral circulation are low.
Using polyclonal activation and high doses of IL-2 to expand Tregs
could provide the necessary number for therapeutic efficacy. How-
ever, intensive expansion protocols could compromise purity of
Tregs at the end of the culture protocol. These limitations may
be in part due to the presence of “contaminating” Teffs within
bead-separated Treg preparations; however the capacity for con-
version of human Tregs into IL-17-producing cells has also been
well demonstrated (see above). To this aim, the application of
tolerogenic approaches to both enhance Treg expansion in vitro
and stabilize their suppressive phenotype has been investigated in
recent years. Rapamycin, an mTOR kinase inhibitor, for exam-
ple, selectively promotes expansion of suppressive human Tregs
(Battaglia et al., 2006; Scotta et al., 2012). Likewise, culture of
Tregs in vitro in the presence of ATRA also supports expansion of
functional FOXP3+ human Tregs (Scotta et al., 2012). In contrast,
only Treg cultures propagated in the absence of Rapamycin con-
tain CD161+ Tregs, the precursor population of IL-17-producing
Tregs (Tresoldi et al., 2011; Scotta et al., 2012). Thus, culture of
Tregs with a combination of Rapamycin and clinically acceptable
retinoic acid-related molecules may be a viable option to gener-
ate large numbers of suppressive and stable Tregs with limited
IL-17 potential (Golovina et al., 2011; Scotta et al., 2012). How-
ever, among the first Treg-based cell therapy trials in humans (for
the treatment of GvHD and type 1 diabetes mellitus respectively),
two have used no drug supplementation (except for IL-2) during
ex vivo expansion of Tregs and neither has reported unexpected
side effects nor paradoxical exacerbation of disease in patients
(Trzonkowski et al., 2009; Marek-Trzonkowska et al., 2012).
Neither of the first two approaches, however, makes a distinc-
tion between tTregs and iTregs as the starting population. Indeed,
culture of contaminating Teffs in the presence of Rapamycin or
ATRA during Treg expansion would support the development of
iTregs, as discussed above. Thus, the third approach for Treg-
based therapy is the induction of iTregs in vivo. As previously
discussed, induction of Tregs in the periphery, whether Foxp3+
or Foxp3- can be achieved through a variety of means. Therapeu-
tic options can therefore include administration of tolerogenic
DCs that support the in vivo development of both iTregs and Tr1
cells (Naranjo-Gómez et al., 2011; Boks et al., 2012), injection of
in vitro expanded Tr1 cells (Brun et al., 2009; Desreumaux et al.,
2012) or the introduction of regulatory macrophages (Mregs – not
discussed here).
Although these data provide only the earliest evidence for the
clinical application of Tregs in cell therapy, a strategy to use these
approaches in solid organ transplantation is under way. The ONE
Study, for instance, is a multi-center phase I/II study, funded by the
European Union FP7 program, investigating the safety of infusing
ex vivo generated/expanded Tregs, Tr1 cells, Mregs and tolero-
genic DC into kidney transplanted recipients. Altogether, about
200 patients will be enrolled in this clinical trial and, importantly,
every center will use the same immunosuppressive protocol for
both cell therapy as well as control arms. All patients will be
extensively monitored, to obtain data regarding safety, pharma-
codynamics, and efficacy of cell therapy, providing an extensive
data set for future clinical trials.
CONCLUSION
Immunological homeostasis is a delicate balance in which both
excessive and suboptimal responses can lead to pathological states.
CD4+ T cells can differentiate to different Th subsets and promote
either an inflammatory response (Th1, Th2, and Th17) or a regu-
latory one (Tregs). Are then Tregs always beneficial for the optimal
resolution of homeostatic challenges? As always, when considering
immunological homeostasis, the situation is similar to“Goldilocks
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and the three bears.” While Tregs are essential to prevent autoim-
mune disease (Asano et al., 1996) and minimize inflammatory
immune responses against dietary antigens and commensal flora
(Izcue et al., 2006), excessive Treg responses may facilitate tumor
growth and chronic infections by limiting anti-tumor (Shimizu
et al., 1999) or anti-pathogen responses (Sakaguchi, 2005). Thus,
Tregs function must be tightly regulated to ensure responses are
appropriate for each pathological scenario (reviewed in Belkaid,
2007).
Regulatory T cells are both centrally derived and peripherally
induced and include both Foxp3+ and Foxp3− populations of
cells. An understanding of the mechanisms of Treg induction,
suppressive function and lineage stability is key to unraveling the
causes underlying development of autoimmune diseases and the
design of studies employing Tregs as therapeutic tools in the clinic.
Important questions include which regulatory population(s) we
should use, whether/how they should be expanded in vitro or
induced in vivo, what role infectious tolerance will play, whether
Treg plasticity will pose a significant problem and whether the
epigenetic/miRNA profile should/could be exploited. On the other
hand, lineage plasticity could in theory allow the conversion of
effector Th1 and Th17 cells into functioning Tregs in a therapeutic
manner. Increasing numbers of clinical trials are focusing on the
use of Tregs in a clinical setting, suggesting that Treg-based therapy
is considered as both a feasible and acceptable approach to treat
inflammatory diseases, offering an alternative to standard phar-
macological care. Answers to the questions posed here should,
therefore, be forthcoming.
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